- Home
- CYH vs PLRX Comparison
CYH vs PLRX Comparison
Compare CYH & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYH | PLRX |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.2M | 81.7M |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CYH | PLRX |
|---|---|---|
| Price | $2.96 | $1.34 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 7 | 4 |
| Target Price | ★ $3.57 | $2.67 |
| AVG Volume (30 Days) | ★ 1.3M | 526.3K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 196.67 | 29.97 |
| EPS | ★ 3.77 | N/A |
| Revenue | ★ $12,485,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.17 | N/A |
| P/E Ratio | $0.79 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.24 | $1.09 |
| 52 Week High | $4.43 | $1.95 |
Technical Indicators
Market Signals| Indicator | CYH | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.80 | 56.90 |
| Support Level | $2.94 | $1.12 |
| Resistance Level | $3.25 | $1.39 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 31.03 | 79.25 |
Price Performance
Historical ComparisonAbout CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.